5 completed, 1 terminated, 1 unknown. 4 Phase 2, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 3, Unknown 1 |
| Phase 3 | 3 | Completed 2, Terminated 1 |
Follow LIPO-202: new trials by email Literature Review of LIPO-202 trials Research Report on LIPO-202
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Safety and Efficacy of LIPO-202 for the Reduction of Submental Subcutaneous Fat LIPO-202, Placebo for LIPO-202 - Submental Fat | Phase 2 | Completed | Neothetics, Inc | 162 | 2016-12-22 | 2017-10-20 |
| Safety and Efficacy Study of LIPO-202 for the Reduction of Central Abdominal Bulging in Obese Subjects LIPO-202, Placebo - Central Abdominal Bulging | Phase 2 | Completed | Neothetics, Inc | 120 | 2015-09-01 | 2015-12-24 |
| Extension Study to Evaluate the Post-Treatment Safety and Duration of Clinical Effect of LIPO-202 LIPO-202, Placebo - Central Abdominal Bulging | Phase 3 | Terminated | Evofem Inc. | 100 | 2015-06-01 | 2019-12-10 |
| Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat (AbCONTOUR2) LIPO-202, Placebo - Central Abdominal Bulging | Phase 3 | Completed | Evofem Inc. | 793 | 2015-04-09 | 2019-01-07 |
| Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat LIPO-202, Placebo - Central Abdominal Bulging | Phase 3 | Completed | Neothetics, Inc | 800 | 2015-04-01 | 2016-01-08 |
| An Open-Label Study to Evaluate Retreatment With LIPO-202 LIPO-202 - Central Abdominal Bulging | Phase 2 | Unknown | Neothetics, Inc | 150 | 2015-03-01 | 2015-08-13 |
| Dose Ranging Study Drug: salmeterol xinafoate, Drug: Placebo - Periumbilical Subcutaneous Adipose Tissue Reduction | Phase 2 | Completed | Neothetics, Inc | 472 | 2013-02-01 | 2015-03-26 |
Neothetics, Inc (5) · Evofem Inc. (2)
United States (6)
Maria Feldman (5) · Daniel Piacquadio, MD (1) · Murray C Maytom, MBChB, MBA (1)